Immunosuppressant drugs essential

Ecample Miller and Rich investigated the conformational consequences of substitutions on an amino acid in cyclosporin A, an important immunosuppressive drug. One of the amino acids in this cyclic undecapeptide is (2, 3r, 4r, 6e)-3-Hydroxy-4-methyl-2-(methylamino)-6-octenoic acid (MeBmt). It is essential for biological activity. 

Immunophillins are abundant proteins that catalyze the cis-trans isomerization of proline residues within proteins, generally to aid in protein folding. Immunophillins are not essential proteins, are the intracellular binding proteins of several immunosuppressive drugs. Cyclosporin A exerts its action after binding to cyclophilin. Tacrolimus and sirolimus predominantly bind to the protein FKBP-12 (FK binding protein-12). 

A comprehensive review of systems, physical examination, ocular examination, and laboratory testing with a multidisciplinary approach to determine the etiology of IK is essential. Treatment should be aimed at addressing any underlying systemic disease and may involve the use of systemic steroids or immunosuppressive drug therapy depending on the cause. 

A number of chemicals with demonstrable suppression of immune function produce this action via indirect effects. By and large, the approach that has been most frequently used to support an indirect mechanism of action is to show immune suppression after in vivo exposure but no immune suppression after in vitro exposure to relevant concentrations. One of the most often cited mechanisms for an indirect action is centered around the limited metabolic capabilities of immunocompetent cells and tissues. A number of chemicals have caused immune suppression when administered to animals but were essentially devoid of any potency when added directly to suspensions of lymphocytes and macrophages. Many of these chemicals are capable of being metabolized to reactive metabolites, including dime-thylnitrosamine, aflatoxin Bi, and carbon tetrachloride. Interestingly, a similar profile of activity (i.e., suppression after in vivo exposure but no activity after in vitro exposure) has been demonstrated with the potent immunosuppressive drug cyclophosphamide. With the exception of the PAHs, few chemicals have been demonstrated to be metabolized when added directly to immunocompetent cells in culture. A primary role for a reactive intermediate in the immune suppression by dimethylnitrosamine, aflatoxin Bi, carbon tetrachloride, and cyclophosphamide has been confirmed in studies in which these xenobiotics were incubated with suspensions of immunocompetent cells in the presence of metabolic activation systems (MASs). Examples of MASs include primary hepatocytes, liver microsomes, and liver homogenates. In most cases, confirmation of a primary role for a reactive metabolite has been provided by in vivo studies in which the metabolic capability was either enhanced or suppressed by the administration of an enzyme inducer or a metabolic inhibitor, respectively. 

Each of the collagen-vascular diseases has its own recommended form of therapy. For most of these diseases, there are few well-controlled clinical trials evaluating pharmacotherapy. Treatment of most of these diseases requires anti-inflammatory or immunosuppressive drugs. Monitoring therapeutic outcomes is essential because drugs and drug doses may need to be modified frequently. 

Perhaps the most effective immunosuppressive drugs in routine use are the calcineurin inhibitors, cyclosporine and tacrolimus, which target intracellular signaling pathways induced as a consequence of T-ceU-receptor activation. Although they are structurally unrelated and bind to distinct molecular targets, they inhibit normal T-ceU signal transduction essentially by the same mechanism (see Figure 52-1). 

In a similar fashion, it has been possible to isolate different conformations of the immunosuppressive drug, cyclosporin A. By preparing anhydrous THF solutions of CsA, with and without 0.4 M LiCl, it was possible to restrict the peptide ring system conformation in CsA to trans and cis conformers. Addition of these conformers separately to the assay buffer enabled the dissociation constants of both the cis and trans amide bond conformers in CsA for inhibition of PPIase to be determined. The trans conformer (2337t) is very active the cis conformer (23.37c) is not, and these plus other data were used to show that CsA adopts a conformation in water that is very close to the enzyme-bound CsA conformation. Subsequently, Wenger and coworkers at Sandoz (now Novartis) showed by NMR experiments that a 3-substituted CsA derivative, e.g. (23.38) (Fig. 23.8) adopts a conformation in water that is essentially identical... 

Dlhydrofplate Reductase Inhibitors - This enzyme (DHFF) reduces dlhydrofollc acid (] ) to tetrahydrofollc acid - an essential cofactor with important roles In DNA synthesis and cell growth. DHFR can be widely different In structure in different cells, and Inhibitors which exploit these differences Include clinically useful antibacterial, antiprotozoal, Immunosuppressant and antlneoplastlc drugs. A vast amount of synthetic analog work in this field has been done, much of it by Baker.68 Hansch and co-workers used data from several groups and QSAR techniques to "map" receptor space for DHFR from rat liver, from... 

Mycophenolate mofetil (Cellcept) is an immunosuppressant approved for prophylaxis of organ rejection in patients with renal, cardiac, and hepatic transplants. Myco-phenolic acid, the active derivative of mycophenolate mofetil, inhibits the enzyme inosine monophosphatase dehydrogenase (IMPDH), thereby depleting guanosine nucleotides essential for DNA and RNA synthesis. Moreover, mycophenolic acid is a fivefold more potent inhibitor of the type 11 isoform of IMPDH found in activated B- and T-lymphocytes and thus functions as a specific inhibitor of T- and B-lymphocyte activation and proliferation. The drug also may enhance apoptosis. 

---